Literature DB >> 12208474

Transgenic overexpression of human lecithin: cholesterol acyltransferase (LCAT) in mice does not increase aortic cholesterol deposition.

James W Furbee1, John S Parks.   

Abstract

Results from several atherosclerosis studies using morphometric procedures have proven controversial with regard to whether over-expression of human LCAT in transgenic (Tg) mice is atherogenic. The purpose of the present study was to determine the effect of 10-fold over-expression of human LCAT on aortic free and esterified cholesterol (EC) deposition as well as plasma lipoprotein cholesteryl ester (CE) fatty acid composition in mice fed an atherogenic diet containing cholic acid. C57Bl/6 (control) and human LCAT-Tg mice were fed chow or an atherogenic diet (15% of calories from palm oil, 1.0% cholesterol and 0.5% cholic acid) for 24 weeks before measurement of aortic cholesterol content. Compared with the chow diet, control and LCAT-Tg mice fed the atherogenic diet had a 2-fold increase in plasma total, free and EC, a 7-fold increase in plasma apoB lipoprotein cholesterol, and a 40-50-fold increase in hepatic cholesterol content. The aortic EC content was increased in control (0.7 vs. 1.2 mg/g protein) and LCAT-Tg (0.3 vs. 1.5 mg/g protein) mice fed the atherogenic diet compared with those consuming the chow diet; however, there was no difference in aortic free (14.4+/-6.8 vs. 18.5+/-7.7 mg/g protein) or esterified (1.2+/-1.0 vs. 1.5+/-1.2 mg/g protein) cholesterol content between atherogenic diet-fed control and LCAT-Tg mice, respectively. LCAT-Tg mice fed the atherogenic diet had a 2-fold increase in the ratio of saturated+monounsaturated to polyunsaturated CE species in plasma apoB lipoproteins compared with control mice (9.4+/-2.4 vs. 4.9+/-0.7). We conclude that over-expression of human LCAT in Tg mice fed an atherogenic diet containing cholic acid does not result in increased aortic cholesterol deposition compared with control mice, even though the CE fatty acid saturation index of plasma apoB lipoproteins was doubled.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12208474     DOI: 10.1016/s0021-9150(02)00201-0

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  14 in total

Review 1.  The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?

Authors:  Menno Vergeer; Adriaan G Holleboom; John J P Kastelein; Jan Albert Kuivenhoven
Journal:  J Lipid Res       Date:  2010-04-06       Impact factor: 5.922

2.  Macrophage 12/15 lipoxygenase expression increases plasma and hepatic lipid levels and exacerbates atherosclerosis.

Authors:  Shunxing Rong; Qiang Cao; Mingxia Liu; Jeongmin Seo; Lin Jia; Elena Boudyguina; Abraham K Gebre; Perry L Colvin; Thomas L Smith; Robert C Murphy; Nilamadhab Mishra; John S Parks
Journal:  J Lipid Res       Date:  2012-01-25       Impact factor: 5.922

3.  Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo.

Authors:  Hiroyuki Tanigawa; Jeffrey T Billheimer; Jun-ichiro Tohyama; Ilia V Fuki; Dominic S Ng; George H Rothblat; Daniel J Rader
Journal:  Circulation       Date:  2009-06-29       Impact factor: 29.690

Review 4.  HDL-targeted therapies: progress, failures and future.

Authors:  Bronwyn A Kingwell; M John Chapman; Anatol Kontush; Norman E Miller
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

Review 5.  Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor?

Authors:  Xavier Rousset; Robert Shamburek; Boris Vaisman; Marcelo Amar; Alan T Remaley
Journal:  Curr Atheroscler Rep       Date:  2011-06       Impact factor: 5.113

6.  Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Emily L Willner; Bryan Tow; Kimberly K Buhman; Martha Wilson; David A Sanan; Lawrence L Rudel; Robert V Farese
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

7.  Lecithin: cholesterol acyltransferase and atherosclerosis: another high-density lipoprotein story that doesn't quite follow the script.

Authors:  Daniel J Rader
Journal:  Circulation       Date:  2009-08-03       Impact factor: 29.690

8.  Reduction in dietary omega-6 polyunsaturated fatty acids: eicosapentaenoic acid plus docosahexaenoic acid ratio minimizes atherosclerotic lesion formation and inflammatory response in the LDL receptor null mouse.

Authors:  Shu Wang; Dayong Wu; Nirupa R Matthan; Stefania Lamon-Fava; Jaime L Lecker; Alice H Lichtenstein
Journal:  Atherosclerosis       Date:  2008-09-02       Impact factor: 5.162

9.  A Systematic Investigation of Structure/Function Requirements for the Apolipoprotein A-I/Lecithin Cholesterol Acyltransferase Interaction Loop of High-density Lipoprotein.

Authors:  Xiaodong Gu; Zhiping Wu; Ying Huang; Matthew A Wagner; Camelia Baleanu-Gogonea; Ryan A Mehl; Jennifer A Buffa; Anthony J DiDonato; Leah B Hazen; Paul L Fox; Valentin Gogonea; John S Parks; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2016-01-21       Impact factor: 5.157

Review 10.  Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?

Authors:  Sandra Kunnen; Miranda Van Eck
Journal:  J Lipid Res       Date:  2012-05-07       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.